Delcath Systems (NASDAQ:DCTH) Issues Earnings Results

Delcath Systems (NASDAQ:DCTH) issued its quarterly earnings data on Thursday. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.07, FiscalAI reports. The firm had revenue of $24.99 million during the quarter, compared to analyst estimates of $23.51 million. Delcath Systems had a return on equity of 0.51% and a net margin of 0.62%.

Here are the key takeaways from Delcath Systems’ conference call:

• Q1 operational momentum: the company activated 4 centers, reported record new patient starts, has 29 REMS‑certified sites and is modifying its activation goal to 37 centers by year‑end (40 by Q1 2027), reflecting broad commercial interest.
• Strong topline and guidance: Q1 revenue rose to $25.0M (vs $19.8M LY), ending cash of $89.3M, and management reiterated at least $100M revenue for 2026 with expected positive adjusted EBITDA for the remainder of the year.
• Clinical programs progressing but paced slowly: the metastatic CRC trial has 13 active screening sites with 7 patients enrolled (target 26 sites by year‑end; interim readout late 2027) and the metastatic breast program has 4 sites active with a target of 15 by late 2026, so readouts remain long‑dated and enrollment is ramping.
• CHOPIN data driving adoption: publication of the CHOPIN results in The Lancet Oncology (combination HEPZATO + immunotherapy showing ~76% response and survival separation) is cited as a key factor changing prescribing patterns and motivating many new sites to adopt a CHOPIN‑like protocol.

Delcath Systems Stock Up 2.1%

DCTH traded up $0.24 during trading on Friday, hitting $11.48. 569,665 shares of the company traded hands, compared to its average volume of 339,366. The firm has a market cap of $395.60 million, a P/E ratio of 1,148.00 and a beta of 0.54. The stock’s fifty day moving average is $9.86 and its 200 day moving average is $9.82. Delcath Systems has a one year low of $8.12 and a one year high of $18.23.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on DCTH shares. BTIG Research cut their target price on Delcath Systems from $23.00 to $19.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. Wall Street Zen downgraded Delcath Systems from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Delcath Systems in a research note on Friday, January 9th. Finally, Evercore set a $27.00 target price on Delcath Systems in a research note on Thursday, February 26th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

Hedge Funds Weigh In On Delcath Systems

Several institutional investors have recently bought and sold shares of the company. XTX Topco Ltd lifted its stake in Delcath Systems by 339.4% in the fourth quarter. XTX Topco Ltd now owns 71,193 shares of the company’s stock valued at $719,000 after purchasing an additional 54,990 shares during the last quarter. Millennium Management LLC lifted its stake in Delcath Systems by 3.0% in the fourth quarter. Millennium Management LLC now owns 246,444 shares of the company’s stock valued at $2,489,000 after purchasing an additional 7,190 shares during the last quarter. Man Group plc lifted its stake in Delcath Systems by 34.1% in the fourth quarter. Man Group plc now owns 38,158 shares of the company’s stock valued at $385,000 after purchasing an additional 9,705 shares during the last quarter. Balyasny Asset Management L.P. lifted its stake in Delcath Systems by 69.5% in the fourth quarter. Balyasny Asset Management L.P. now owns 52,140 shares of the company’s stock valued at $527,000 after purchasing an additional 21,384 shares during the last quarter. Finally, Jump Financial LLC lifted its stake in Delcath Systems by 68.0% in the fourth quarter. Jump Financial LLC now owns 45,953 shares of the company’s stock valued at $464,000 after purchasing an additional 18,596 shares during the last quarter. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.